Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Greenstone Biosciences, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.
Cardiovascular disease is the leading cause of morbidity and mortality. The development of cardiovascular disease includes both genetic and epigenetic factors. Understanding their molecular and cellular mechanism is necessary to identify novel drug targets and treat the disease. Present in vitro and in vivo models of the disease do not mimic human pathophysiology, and obtaining the primary cells from the patients for the studies relevant to the cardiovascular and pulmonary system is difficult. Induced pluripotent stem cells (iPSCs) are derived from a person's blood cells and facilitate the discovery of cardiovascular disease mechanisms. The Investigators propose recruiting cardiovascular patients from diverse ethnic backgrounds and creating a rich clinical database using REDCap. Blood samples will be obtained from participants and used to create iPSCs. The participant will have DNA sequencing, and serum will be analyzed for protein biomarkers. The multi-omics data and reprogrammed iPSCs will be stored in the Cardiology and Critical Care (C3RP) laboratory at the Robarts Research Institute at Western University. The reprogrammed iPSCs can generate a limitless supply of cardiovascular tissue. Moreover, the iPSC-derived data will be correlated with clinical information, genetic sequencing, and protein biomarkers from serum analysis. The Investigators expect to create an iPSC biobank coupled with a rich clinical dataset, including genetic sequencing analysis and protein biomarkers that will enable the discovery of novel biomarkers and drug targets for cardiovascular disease.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| study controls | Healthy control participants (n=50) aged 80 and older enrolled in the study with no known CVD or history of significant medical problems. | ||
| cardiovascular disease | Participants with cardiovascular disease (n=150) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| REDCap Database | Identify patients with cardiovascular disease from ethnically diverse backgrounds and create a clinical database with REDCap. | 10 years |
| Induced pluripotent stem cell (iPSC) Biobank | Reprogram peripheral blood mononuclear cells (PBMC) to iPSCs. | 10 years |
| Differentiation into Cardiovascular lineages | Differentiate of iPSCs into different cardiovascular lineages (endothelial cells, smooth muscle cells, cardiomyocytes, etc.) | 10 years |
| Molecular profiling of participants | Molecular profiling of iPSC-derived tissue and patient serum using microarray, DNA sequencing, and high throughput "omics" technologies (transcriptomic analysis, proteomic analysis, metabolomic studies, and functional assays). | 10 years |
| Bioinformatics analysis | Bioinformatics analysis of clinical, iPSC disease modeling, and serum omics analysis. | 10 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
We will recruit 200 participants including 150 patients with cardiovascular disease and 50 healthy control participants.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| London Regional Health Science Centre | Recruiting | London | Ontario | N6A 5A5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Investigators propose collecting two blood samples of 10 mL each from healthy donors and patients in two tubes containing the anticoagulants heparin and ethylenediaminetetraacetic acid (EDTA), respectively. Blood collection and immediate processing have a higher impact on the results of research and laboratory studies.
Collected blood samples will be layered over lymphoprep (Stemcell Technologies) in SepMateTM tubes (Stem cell Technologies). Based on density gradient centrifugation the PBMC is isolated by centrifugation, at 2000 rpm for 10 min, transferred, and washed with RPMI media for 5 mins at 1500 rpm. The collected PBMCs are cryopreserved at -196˚C at the C3RP facility.
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D001145 | Arrhythmias, Cardiac |
| D009202 | Cardiomyopathies |
| D006333 | Heart Failure |
| D020521 | Stroke |
| D006330 | Heart Defects, Congenital |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided